Get the Stockscreener App
10.84
0.09%
-0.125
Artiva Biotherapeutics Inc stock is traded at $10.84, with a volume of 4,259.
It is down -0.09% in the last 24 hours and up +4.48% over the past month.
Artiva Biotherapeutics Inc is a biopharmaceutical company. The company is engaged in advancing a pipeline of off-the-shelf, allogeneic NK cell therapies for the treatment of hematologic malignancies or solid tumors. The pipeline program of the company includes Artiva-Funded Trials and Collaborator-Funded Trials.
See More
Previous Close:
$10.96
Open:
$11.26
24h Volume:
4,259
Relative Volume:
0.03
Market Cap:
$272.50M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+4.19%
1M Performance:
+4.48%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$10.74
$11.30
1-Week Range:
$10.00
$11.57
52-Week Range:
$9.68
$17.31
Artiva Biotherapeutics Inc Stock (ARTV) Company Profile
Name
Artiva Biotherapeutics Inc
Sector
Industry
Phone
(858) 267-4467
Address
5505 MOREHOUSE DRIVE, SAN DIEGO
Compare ARTV with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
| ARTV | 11.26 | 272.50M | 0 | 0 | 0 | 0.00 |
| VRTX | 445.46 | 115.74B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 736.00 | 81.65B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 585.04 | 34.86B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 247.45 | 32.09B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 102.20 | 24.49B | 3.30B | -501.07M | 1.03B | 11.54 |
Artiva Biotherapeutics Inc Stock (ARTV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-13-24 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-13-24 | Initiated | Jefferies | Buy |
| Aug-13-24 | Initiated | Needham | Buy |
| Aug-13-24 | Initiated | TD Cowen | Buy |
| Aug-13-24 | Initiated | Wedbush | Outperform |
Artiva Biotherapeutics Inc Stock (ARTV) Latest News
Cantor Fitzgerald Forecasts ARTV FY2024 Earnings - Defense World
Cantor Fitzgerald Weighs in on ARTV FY2024 Earnings - MarketBeat
Wedbush Has Bearish Estimate for ARTV FY2024 Earnings - Defense World
Wedbush Lowers Earnings Estimates for Artiva Biotherapeutics - MarketBeat
Needham & Company LLC Reiterates Buy Rating for Artiva Biotherapeutics (NASDAQ:ARTV) - Defense World
Artiva Biotherapeutics (NASDAQ:ARTV) Issues Quarterly Earnings Results, Misses Estimates By $0.24 EPS - MarketBeat
Artiva Biotherapeutics Reports Q3 2024 Financial Results - TipRanks
Artiva Biotherapeutics (NASDAQ:ARTV) Earns Buy Rating from Needham & Company LLC - MarketBeat
Artiva Biotherapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights - GlobeNewswire
Artiva Biotherapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Artiva Biotherapeutics to Participate in the Jefferies London Healthcare Conference - The Manila Times
Artiva Bio to Present at Jefferies Healthcare Conference, Spotlight on Cell Therapy Pipeline | ARTV Stock News - StockTitan
Artiva Biotherapeutics (NASDAQ:ARTV) vs. Iovance Biotherapeutics (NASDAQ:IOVA) Critical Review - Defense World
Cell therapy developer Artiva refiles for a $100M IPO - MSN
Artiva Biotherapeutics appoints new board member By Investing.com - Investing.com Australia
Artiva Biotherapeutics Appoints Alison Moore, Ph.D., to Its Board of Directors - ForexTV.com
Artiva Biotherapeutics, Inc. Appoints Alison Moore as an Independent Member of Its Board of Directors - Marketscreener.com
Artiva Biotherapeutics appoints new board member - Investing.com
Artiva, Century, others extend natural-killer autoimmune push - BioWorld Online
Artiva Biotherapeutics (NASDAQ:ARTV) Stock Price Down 5.4%Time to Sell? - MarketBeat
Wall Street SWOT: Artiva Biotherapeutics stockNK cell pioneer targets autoimmune market By Investing.com - Investing.com South Africa
The Attractiveness of Investing In Artiva Biotherapeutics Inc (ARTV) is Growing - Knox Daily
Last Week's 3 Biotech IPOs Prompt Huge Insider Buying - 24/7 Wall St.
Artiva Biotherapeutics (NASDAQ:ARTV) Trading 6.2% Higher - MarketBeat
Artiva Biotherapeutics to Participate in the 2024 Cantor Fitzgerald Global Healthcare Conference - GlobeNewswire
Artiva Biotherapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights - GlobeNewswire
Artiva Biotherapeutics, Inc.’s (NASDAQ:ARTV) Quiet Period Will End on August 28th - Defense World
Artiva Biotherapeutics, Inc.'s Quiet Period Set To Expire on August 28th (NASDAQ:ARTV) - MarketBeat
Brokers Issue Forecasts for Artiva Biotherapeutics, Inc.'s Q2 2024 Earnings (NASDAQ:ARTV) - MarketBeat
Analysts Set Expectations for Artiva Biotherapeutics, Inc.’s Q2 2024 Earnings (NASDAQ:ARTV) - Defense World
Artiva Biotherapeutics (NASDAQ:ARTV) Stock Quotes, Forecast and News Summary - Benzinga
Artiva Biotherapeutics' Investigational Scalable Cell Therapies For Autoimmune Disorders, Analyst Initiate With Bullish Pitch - Benzinga
Artiva Biotherapeutics (NASDAQ:ARTV) Receives New Coverage from Analysts at TD Cowen - Defense World
Needham & Company LLC Initiates Coverage on Artiva Biotherapeutics (NASDAQ:ARTV) - Defense World
Wedbush Initiates Coverage on Artiva Biotherapeutics (NASDAQ:ARTV) - Defense World
Artiva Biotherapeutics (NASDAQ:ARTV) Coverage Initiated by Analysts at Jefferies Financial Group - MarketBeat
Artiva Biotherapeutics (NASDAQ:ARTV) Coverage Initiated by Analysts at Cantor Fitzgerald - Defense World
Non-Hodgkin Lymphoma Drugs Pipeline 2024 | Novartis, AstraZeneca, Genentech, BioInvent, Genmab, SystImmune, Nordic Nanovector, Pacylex Pharmaceuticals, Artiva Biotherapeutics, Inc - Barchart
July IPOs to Watch in Tech, Biotech, Food Security and Transportation - Investorideas.com newswire
Insider Buying in These 2 IPOs Is Huge, Plus Financial CEOs Pick Up Shares - 24/7 Wall St.
Week In Review: Nanjing Triastek Partners With BioNTech In A $1.2 Billion Drug Development Deal - Seeking Alpha
Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Director Yong-Jun Huh Buys 2,083,332 Shares - Defense World
Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Major Shareholder Global Strategic Fund I. Venbio Purchases 416,666 Shares - Defense World
VenBio fund acquires $5m in Artiva Biotherapeutics stock By Investing.com - Investing.com Australia
VenBio fund acquires $5m in Artiva Biotherapeutics stock - Investing.com India
Artiva Biotherapeutics sees major stock purchases by GC Corp entities - Investing.com South Africa
Artiva Biotherapeutics director Yong-Jun Huh buys $25m in IPO By Investing.com - Investing.com South Africa
Artiva Biotherapeutics director Yong-Jun Huh buys $25m in IPO - Investing.com India
Artiva Biotherapeutics Inc Stock (ARTV) Financials Data
There is no financial data for Artiva Biotherapeutics Inc (ARTV). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
0.42%
0.16%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):